The rapid unwinding of China's COVID restrictions in December triggered a wave of stockpiling of antiviral drugs, including Pfizer's Paxlovid, but access to that treatment has been limited due to low domestic supply. That opened the door to a thriving black market for Indian generic versions and copies that turned out to be fake.




